Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Receivables (2016 - 2025)

Historic Receivables for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $722000.0.

  • Cartesian Therapeutics' Receivables fell 8757.1% to $722000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $722000.0, marking a year-over-year decrease of 8757.1%. This contributed to the annual value of $872000.0 for FY2024, which is 9014.8% down from last year.
  • As of Q3 2025, Cartesian Therapeutics' Receivables stood at $722000.0, which was down 8757.1% from $354000.0 recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Receivables registered a high of $35.5 million during Q2 2024, and its lowest value of $354000.0 during Q2 2025.
  • Its 5-year average for Receivables is $8.7 million, with a median of $7.2 million in 2022.
  • In the last 5 years, Cartesian Therapeutics' Receivables soared by 45141.3% in 2024 and then tumbled by 9900.31% in 2025.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Receivables stood at $9.9 million in 2021, then dropped by 1.57% to $9.8 million in 2022, then decreased by 9.29% to $8.9 million in 2023, then tumbled by 90.15% to $872000.0 in 2024, then fell by 17.2% to $722000.0 in 2025.
  • Its last three reported values are $722000.0 in Q3 2025, $354000.0 for Q2 2025, and $1.8 million during Q1 2025.